Risk Factors of Ototoxicity After Cisplatin-Based Chemo-Irradiation in Patients With Locally Advanced Head-and-Neck Cancer: A Multivariate Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 5, 2007, Pages 1320-1325

  Zuur, Charlotte L ^a   Simis, Yvonne J ^a   Lansdaal, Pauline E ^b   Hart, Augustinus A ^b   Rasch, Coen R ^b   Schornagel, Jan H ^b   Dreschler, Wouter A ^a   Balm, Alfons J ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Cisplatin; Head and neck cancer; Hearing loss; Multivariate analysis; Radiotherapy

Indexed keywords

BIOMEDICAL ENGINEERING; HEALTH RISKS; MULTIVARIANT ANALYSIS; ONCOLOGY; RADIOTHERAPY;

CISPLATIN; HEAD-AND-NECK CANCER; HEARING CAPABILITY; HEARING LOSS;

RADIATION DAMAGE;

CISPLATIN; SODIUM THIOSULFATE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

AGE FACTORS; ANTIDOTES; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HEARING; HEARING LOSS, SENSORINEURAL; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RISK FACTORS; THIOSULFATES;

EID: 34547426366     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.042     Document Type: Article

References (30)

1. Sankaranarayanan R., Masuyer E., Swaminathan R., et al. Head and neck cancer: A global perspective on epidemiology and prognosis. Anticancer Res 18 (1998) 4779-4786
2. Robbins K.T., Storniolo A.M., Kerber C., et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 12 (1994) 2113-2120
3. Robbins K.T., Vicario D., Seagren S., et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg 168 (1994) 419-422
4. Robbins K.T., Kumar P., Wong F.S., et al. Targeted chemoradiation for advanced head and neck cancer: Analysis of 213 patients. Head Neck 22 (2000) 687-693
5. Balm A.J., Rasch C.R., Schornagel J.H., et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 26 (2004) 485-493
6. Madasu R., Ruckenstein M.J., Leake F., et al. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 123 (1997) 978-981
7. Kopelman J., Budnick A.S., Sessions R.B., et al. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98 (1988) 858-864
8. Fleming S., Ratanatharathorn V., Weaver A., et al. Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Am J Clin Oncol 8 (1985) 302-306
9. Myers S.F., Blakley B.W., Schwan S., et al. The "plateau effect" of cis-platinum-induced hearing loss. Otolaryngol Head Neck Surg 104 (1991) 122-127
10. Laurell G., and Jungnelius U. High-dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope 100 (1990) 724-734
11. Raaijmakers E., and Engelen A.M. Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation?. A systematic review of the literature. Radiother Oncol 65 (2002) 1-7
12. Johannesen T.B., Rasmussen K., Winther F.O., et al. Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53 (2002) 86-90
13. Van Der Hulst R.J., Dreschler W.A., and Urbanus N.A. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivates. Ann Otol Rhinol Laryngol 97 (1988) 133-137
14. Rubin D.B. Multiple imputation for nonresponse in surveys (1987), John Wiley and Sons Inc, New York
15. Schafer J.L. Analysis of incomplete multivariate data (1997), Chapman and Hall, London
16. Barnard J., and Rubin D.B. Small-sample degrees of freedom with multiple imputations. Biometrika 86 (1999) 948-955
17. Hesterberg T.C. Combining multiple imputation t, chi-square, and f inferences (1998), MathSoft Inc, Seattle
18. Van Houwelingen J.C., and Le Cessie S. Predictive value of statistical models. Stat Med 9 (1990) 1303-1325
19. Ho W.K., Wei W.I., Kwong D.L., et al. Long-term sensorineural deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 21 (1999) 547-553
20. Wang L., Kuo W., Lee K., et al. A long-term study on hearing status in patients with nasopharyngeal carcinoma after radiotherapy. Otol Neurotol 25 (2004) 168-173
21. Pan C., Eisbruch A., Lee J., et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61 (2005) 1393-1402
22. Vermorken J.B., Kapteijn T.S., Hart A.A., et al. Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19 (1983) 53-58
23. Schell M.J., McHaney V.A., Green A.A., et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7 (1989) 754-760
24. Michael II L.M., Sorenson J.M., Samant S., et al. The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation. J Neuro-oncol 72 (2005) 67-75
25. Regine W.F., Valentino J., John W., et al. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study. Head Neck 22 (2000) 543-549
26. Kovács A.F., Schiemann M., and Turowski B. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docebaxel-three year results of a pilot study. J Cranio-Maxillofacial Surg 30 (2002) 112-120
27. Grau C., Moller K., Overgaard M., et al. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 723-728
28. Kwong D., Wei W., Sham J., et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 36 (1996) 281-289
29. National Cancer Institute. Common toxicity criteria (adverse events) (1999) Bethesda, MD, version 2.0
30. Brock P.R., Bellman S.C., Yeomans E.C., et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19 (1991) 295-300